Ipsen S.A. (IPN.PA)
| Previous close | 116.90 |
| Open | 116.60 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 113.90 - 116.80 |
| 52-week range | 99.70 - 130.70 |
| Volume | |
| Avg. volume | 72,710 |
| Market cap | 9.451B |
| Beta (5Y monthly) | 0.65 |
| PE ratio (TTM) | 15.39 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 1.20 (1.05%) |
| Ex-dividend date | 30 May 2024 |
| 1y target est | N/A |
- GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024
Aggregated presentation by day and by market Purchases of own shares from June 10th to 14th 2024 Name of the IssuerIdentity code of the IssuerDay of the transactionIdentity code of the financial instrumentTotal daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code)IPSEN549300M6SGDPB4Z94P1110/06/2024FR00102591505 000122,0351XPARIPSEN549300M6SGDPB4Z94P1111/06/2024FR00102591507 000122,0734XPARIPSEN549300M6SGDPB4Z94P1112/06/2024FR00102591501 863123,202
- GlobeNewswire
IPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024
Aggregated presentation by day and by market Statement of transactions in own shares from June 3 to June 7, 2024 Name of issuer Identification code of issuer (Legal Entity Identifier) Day of transaction Identification code of financial instrument Aggregated daily volume (in number of shares) Daily weighted average price of the purchased shares * Market (MIC Code) IPSEN 549300M6SGDPB4Z94P11 03/06/2024 FR0010259150 3 100 120,9943 XPAR IPSEN 549300M6SGDPB4Z94P11 04/06/2024 FR0010259150 3 100 121,57
- GlobeNewswire
Ipsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis
Iqirvo® (elafibranor) 80 mg tablets is the first new medicine approved in nearly a decade for the treatment of the rare liver disease called primary biliary cholangitis Approval based on positive Phase III ELATIVE trial dataPrimary biliary cholangitis impacts approximately 100,000 people in the US and is growing in global prevalence. If inadequately treated, it can cause liver failureU.S. approval of Iqirvo establishes Ipsen as a leader in the treatment of rare cholestatic liver diseases PARIS,
